SYSTEMIC THERAPY AND PHOTOTHERAPY OF PSORIASIS - THE POTENTIAL RISKS OF CANCER


Cite item

Full Text

Abstract

The relevance of studying psoriasis and its treatment is conditioned by the ever increasing incidence of this condition and frequency of its severe forms. The recent studies on the complications of both psoriasis itself and its treatment have demonstrated the increased risk of associated carcinogenesis. The analysis and systematization of information accumulated to date gives evidence of the relationship between the development of cancer and the application of modern methods for the treatment of psoriasis Moreover, the available data suggest the enhanced risk of cancer in the patients suffering from this disease compared with that in the general population.

About the authors

D. S Kulbiy

Federal state budgetary institution of additional professional education «Central State Medical Academy», Presidential Administration of the President of the Russian Federation

121359, Moscow, Russia

E. S Ponich

Federal state budgetary institution of additional professional education «Central State Medical Academy», Presidential Administration of the President of the Russian Federation

121359, Moscow, Russia

Larisa Sergeevna Kruglova

Federal state budgetary institution of additional professional education «Central State Medical Academy», Presidential Administration of the President of the Russian Federation

Email: kruglovals@mail.ru
MD, PhD, DSc, Prof., head of the Department of Dermatology and Cosmetology, Federal state budgetary institution of additional professional education «Central State Medical Academy», Presidential Administration of the President of Russian Federation, 121359, Moscow, Russia 121359, Moscow, Russia

References

  1. Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М.: МДВ; 2014.
  2. Соколовский Е.В., Круглова Л.С., Понич Е.С. «Болевые» точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015; (5): 42-51.
  3. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. М.: Деловой экспресс; 2016.
  4. Chen Y.J., Wu C.Y., Chen T.J., Shen J.L., Chu S.Y., Wang C.B., Chang Y.T. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J. Am. Acad. Dermatol. 2011; 65(1): 84-91.
  5. Stern R.S., PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J. Am. Acad. Dermatol. 2012; 66(4): 553-62.
  6. Lindelöf B., Eklund G., Lidén S., Stern R.S. The prevalence of malignant tumors in patients with psoriasis. J. Am. Acad. Dermatol. 1990; 22(6, Pt. 1): 1056-60.
  7. Brauchli Y.B., Jick S.S., Miret M., Meier C.R. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J. Invest. Dermatol. 2009; 129(11): 2604-12.
  8. Chiesa Fuxench Z.C., Shin D.B., Ogdie Beatty A, Gelfand J.M. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016; 152(3): 282-90.
  9. Tsai T.F., Wang T.S., Hung S.T., Tsai P.I., Schenkel B., Zhang M., Tang C.H. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J. Dermatol. Sci. 2011; 63(1): 40-46.
  10. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137(3): 280-284.
  11. Круглова Л.С., Моисеев С.В. Блокада интерлейкина-17 - новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017; 26(2): 40-9.
  12. Молочков В.А., Молочков А.В., Хлебникова А.Н., Кунцевич Ж.С. Эпителиальные опухоли кожи. М.: Бином; 2012: 121-61.
  13. Молочков В.А. Меланома и другие злокачественные новообразования кожи. В кн.: Давыдов М.И., Вышковский Г.Л. (ред.) Энциклопедия клинической онкологии: Руководство для практикующих врачей. М.: РЛС; 2005: 341-64.
  14. McGeown C., Christophers E., Schmidtmann B., Guillaume J.C. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 cohort study. J. Invest. Dermatol. 2003; 120(2): 211-6.
  15. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat. Rev. Drug. Discov. 2005; 4(1): 19-34.
  16. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. Am. Acad. Dermatol. 2009; 60(4): 643-59.
  17. Nijsten T.E.C., Stern R.S. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J. Invest. Dermatol. 2003; 121: 252-8.
  18. Hannuksela-Svahn A., Pukkala E., Poikolainen K., Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 2000; 114(3): 587-90.
  19. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 cohort study. J. Invest. Dermatol. 2003;120(2): 211-6.
  20. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994; 73(11): 2759-64.
  21. Алиев М.Д., Бохян Б.Ю., Демидов Л.В., Иванов С.М., Самойленко И.В., Трофимова О.П. и др. Клинические рекомендации по диагностике и лечению больных меланомой кожи. М.; 2014
  22. Stern R.S. The risk of melanoma in association with long-term exposure to PUVA.J. Am. Acad. Dermatol. 2001; 44(5): 755-61.
  23. Stern R.S., Nichols K.T. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N. Engl. J. Med. 1997; 336: 1041-5.
  24. Молочков А.В., Ковригина А.М., Кильдюшевский А.В., Караулов А.В. Лимфома кожи. М.: Бином; 2012.
  25. Лезвинская Е.М., Нефедова Е.Д., Важбин Л.Б., Махнева Н.В. К вопросу о трансформации псориаза в Т-клеточную злокачественную лимфому кожи: клинические наблюдения. Клиническая дерматология и венерология. 2014; 12 (2): 54-60.
  26. Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B.L. The risk of malignancy associated with psoriasis. Arch. Dermatol. 2001;137(6): 778-83.
  27. Brauchli Y.B., Jick S.S., Miret M., Meier C.R. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J. Invest. Dermatol. 2009; 129(11): 2604-12.
  28. Gelfand J.M., Shin D.B., Neimann A.L., Wang X., Margolis D.J., Troxel A.B. The risk of lymphoma in patients with psoriasis. J. Invest. Dermatol. 2006; 126(10): 2194-20.
  29. Stern R.S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch. Dermatol. 2006; 142: 1132-5.
  30. Infliximab Fall Prescribing Information. Horsham: Janssen Biotech, Inc.; 2013.
  31. Papp K.A., Gottlieb A.B., Naldi L. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J. Drugs Dermatol. 2015; 14: 706-14.
  32. Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological. J. Eur. Acad. Dermatol. Venereol. 2014; 28(3): 333-7.
  33. Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009; 301(7): 737-44.
  34. Pinedo-Vega J.L., Castañeda-López R., Dávila-Rangel J.I., Mireles-García F., RíosMartínez C., López-Saucedo A. [Skin cancer incidence in Zacatecas]. Rev. Med. Inst. Mex. Seguro Soc. 2014; 52(3): 282-9.
  35. Lee M.S., Lin R.Y., Chang Y.T., Lai M.S. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int. J. Dermatol. 2012; 51(12): 1454-60.
  36. Chen Y.J., Wu C.Y., Chen T.J., Shen J.L., Chu S.Y. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J. Am. Acad. Dermatol. 2011; 65(1): 84-91.
  37. Prizment A.E., Alonso A., Folsom A.R., Ahmed R.L., Virnig B.A., Warshaw E.M., Anderson K.E. Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study. Cancer Causes Control. 2011; 22(7): 1003-10.
  38. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C. et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 cohort study. J. Invest. Dermatol. 2003; 120(2): 211-6.
  39. Ji J., Shu X., Sundquist K., Sundquist J., Hemminki K. Cancer risk in hospitalized psoriasis patients: a follow-up study in Sweden. Br. J. Cancer. 2009; 100(9): 1499-502.
  40. Frentz G., Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br. J. Dermatol. 1999; 140(2): 237-42.
  41. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., Lindeloe B.F., Berne B., Hannuksela M. et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br. J. Dermatol. 1999; 141: 497-501.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies